Comparative Study
doi: 10.1007/BF01964451.
Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin
Affiliations
- PMID: 2060518
- DOI: 10.1007/BF01964451
Item in Clipboard
Comparative Study
Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin
Eur J Clin Microbiol Infect Dis.
1991 Mar.
Abstract
Five fluoroquinolones were tested against 300 staphylococci from a wide variety of US medical centers including 150 strains resistant to penicillinase-resistant penicillins (PRP-resistant). Ten ciprofloxacin-resistant strains of PRP-resistant Staphylococcus aureus were relatively resistant to the other fluoroquinolones, but the remaining 290 isolates were susceptible to all five drugs at established or anticipated breakpoint concentrations. The relative potency of the study drugs could be ranked as follows: CI-960 greater than PD 131628 greater than sparfloxacin greater than ciprofloxacin greater than ofloxacin. All five drugs were bactericidal against PRP-resistant and PRP-susceptible staphylococci.
Similar articles
-
Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin.Antimicrob Agents Chemother. 1990 Sep;34(9):1843-5. doi: 10.1128/AAC.34.9.1843. Antimicrob Agents Chemother. 1990. PMID: 2285304 Free PMC article.
-
Anti-staphylococcal activity of temafloxacin, ciprofloxacin, ofloxacin and enoxacin.J Antimicrob Chemother. 1991 Nov;28(5):695-9. doi: 10.1093/jac/28.5.695. J Antimicrob Chemother. 1991. PMID: 1663929
-
Activity of new quinolones against ciprofloxacin-resistant staphylococci.Antimicrob Agents Chemother. 1991 Aug;35(8):1679-81. doi: 10.1128/AAC.35.8.1679. Antimicrob Agents Chemother. 1991. PMID: 1656873 Free PMC article.
-
In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.Chemotherapy. 1998 Mar-Apr;44(2):85-93. doi: 10.1159/000007097. Chemotherapy. 1998. PMID: 9551237
-
In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.Diagn Microbiol Infect Dis. 1993 Jul;17(1):85-91. doi: 10.1016/0732-8893(93)90077-k. Diagn Microbiol Infect Dis. 1993. PMID: 8395375
Cited by
-
Penetration of pefloxacin into maxillary sinus cavity and nasal secretions.Eur J Clin Microbiol Infect Dis. 1992 Sep;11(9):828-31. doi: 10.1007/BF01960883. Eur J Clin Microbiol Infect Dis. 1992. PMID: 1468421
-
In vitro antistaphylococcal activities of two investigative fluoroquinolones, CI-960 and WIN 57273, compared with those of ciprofloxacin, mupirocin (pseudomonic acid), and peptide-class antimicrobial agents.Antimicrob Agents Chemother. 1992 Apr;36(4):851-3. doi: 10.1128/AAC.36.4.851. Antimicrob Agents Chemother. 1992. PMID: 1323955 Free PMC article.
-
Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.Drugs. 1996 Jun;51(6):1019-74. doi: 10.2165/00003495-199651060-00010. Drugs. 1996. PMID: 8736621 Review.
-
CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.Antimicrob Agents Chemother. 1992 Jun;36(6):1192-7. doi: 10.1128/AAC.36.6.1192. Antimicrob Agents Chemother. 1992. PMID: 1329613 Free PMC article.
-
In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor.Antimicrob Agents Chemother. 1995 Apr;39(4):964-70. doi: 10.1128/AAC.39.4.964. Antimicrob Agents Chemother. 1995. PMID: 7786004 Free PMC article.
References
-
- Antimicrob Agents Chemother. 1991 Jan;35(1):141-6 - PubMed
-
- Antimicrob Agents Chemother. 1980 Nov;18(5):699-708 - PubMed
-
- Diagn Microbiol Infect Dis. 1989 Sep-Oct;12(5):385-94 - PubMed
-
- Antimicrob Agents Chemother. 1990 Sep;34(9):1843-5 - PubMed
-
- Antimicrob Agents Chemother. 1988 Aug;32(8):1278-81 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials